In win for compounders, FDA will review its decision to put Eli Lilly's tirzepatide on shortage list
In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities Association (OFA), which called the FDA’s decision to remove tirzepatide from the shortage list a “reckless and arbitrary decision—lacking any semblance of lawful process.”
The FDA clarified Thursday that it won't take action against GLP-1 compounders for certain violations while it reevaluates ...
HealthDay on MSN2d
FDA Says Compounding Pharmacies Can Keep Making Weight-Loss Med Tirzepatide, for NowOn October 7, a compounding trade group filed a lawsuit challenging the agency's action, saying there was still a shortage of ...
Health on MSN2d
What the End of a Tirzepatide Shortage Would Mean for Access to Compounded Weight Loss DrugsIn response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...
Facing a lawsuit, the Food and Drug Administration has decided to reconsider its decision to take popular weight-loss and diabetes drugs off of the national shortage list, which will allow compounding ...
A rapid-fire reversal from the Food and Drug Administration has injected even more uncertainty into what was already a wild ...
Weight-loss drugs such as Ozempic, made by Denmark’s Novo Nordisk, can reduce rates of opioid and alcohol abuse by up to 50%, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback